Article
Focus Antitrust: Competition Weekly Email Alert - 12 December 2012
The ECJ has dismissed the appeal brought by AstraZeneca against the judgment of the General Court, which mainly upheld the Commission's Article 102 decision to fine AstraZeneca €60 million for abusing its dominant position relating to its anti-ulcer medicine Losec.

Charles Russell Speechlys LLP
